智通财经APP获悉，艾美疫苗(06660)午后涨超9%，截至发稿，涨5.32%，报4.55港元，成交额876.35万港元。
消息面上，艾美疫苗3月23日发布公告称，mRNA带状疱疹疫苗已于近日获得美国药监局 (FDA)临床试验许可，这是继mRNA RSV疫苗后，短期内公司第二款获得美国FDA批准进入临床试验的又一重磅大单品疫苗，巩固了艾美在mRNA技术赛道的领跑地位，标志着国际化战略又取得了新的里程碑。
此外，艾美疫苗近期发布业绩，公司2024年录得收入12.5亿至13亿之间，同比增加5%至9%；净亏损介乎人民币2.5亿元至2.9亿元之间，减亏幅度85%至87%。复星国际证券认为，2024-2027年艾美收入复合年增长率将达到47%，预计2025年实现盈亏平衡，2027年净利润有望突破15.2亿元人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.